Accelerated continuous theta burst stimulation targeting left primary motor cortex for children with autism spectrum disorder: multicentre randomised sham controlled trial.

12 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Recomputed 4 tests: 4 consistent, 0 inconsistent, 4 via agent-written checks.

1 integrity concern flagged (0 high).

6 copyedit issues flagged: mostly consistency, clarity, grammar.

Checked 70 references: 64 verified — 6 not checked.

1 data/code link checked; 1 live.

The manuscript is ready after minor edits. The most important pre-submission actions are to tone down the overstated claim about 'major advancement', report exact p-values, and add a statement on model assumption verification. Addressing these will strengthen the paper for submission.

1. 1.
   HIGHreporting

   Temper the claim that the protocol is a 'major advancement towards equitable autism care worldwide' in the Discussion; replace with language that acknowledges the preliminary nature of the MCID, short follow-up, and potential biases.

   The current claim is overstated relative to the evidence and will likely be flagged by reviewers or editors.
2. 2.
   HIGHstatistics

   Report exact p-values to 2-3 significant figures (e.g., 'P=0.00023' instead of 'P<0.001') for the primary outcome and all secondary outcomes where currently given as '<0.001'.

   Exact p-values allow readers to assess the strength of evidence more precisely; reviewers expect this standard.
3. 3.
   HIGHstatistics

   Add a subsection in 'Statistical analysis' describing that model assumptions (normality of residuals, homoscedasticity) were checked for the primary linear regression models, and state the method used (e.g., Q-Q plots, residual plots) and any corrective actions taken.

   Verification of assumptions is a standard requirement for linear regression; its absence is a common reviewer concern.
4. 4.
   HIGHrigor

   Add a clear description of outlier handling criteria in the 'Statistical analysis' section: define how outliers were identified (e.g., >3 SD from mean) and whether any data points were excluded or sensitivity analyses performed.

   The paper currently lacks explicit outlier handling, which is a gap in the study design reporting.
5. 5.
   MEDIUMdata code

   Deposit the analysis code in a version-controlled repository (e.g., GitHub, Zenodo) with a permanent DOI, and update the Data availability statement to include this link alongside the OSF link.

   Code in a supplementary appendix is not versioned; a repository with a DOI improves reproducibility and discoverability.
6. 6.
   MEDIUMreporting

   Add a statement indicating whether an independent Data Safety Monitoring Board (DSMB) oversaw the trial, and if so, include details in the 'Methods' section.

   DSMB oversight is standard for clinical trials and enhances transparency.
7. 7.
   MEDIUMreporting

   Provide individual participant data plots (e.g., spaghetti plots or jitter plots) for the primary SRS-2 outcome, either in the main figure or as supplementary material.

   Individual-level data allow readers to assess distribution, outliers, and variability beyond group means and SDs.
8. 8.
   MEDIUMreporting

   Report the exact p-value for the CGI-I analysis at T2 (currently P=0.008) and for the masking integrity test (currently P=0.09) to three significant figures.

   Consistency across the manuscript in reporting exact p-values strengthens statistical reporting.
9. 9.
   MEDIUMreporting

   Consider reporting a pretest measure of treatment expectancy (e.g., credibility/expectancy questionnaire) to formally assess potential expectancy bias, as acknowledged in the limitations.

   Adding this measure would strengthen the analysis of blinding and expectancy effects.
10. 10.
    MEDIUMreporting

    In Table 3, break down 'scalp discomfort' into more specific categories (e.g., 'pain', 'tingling') to provide a more granular safety profile.

    Detailed adverse event reporting improves clinical interpretation and regulatory compliance.
11. 11.
    LOWcopyedit

    In Table 3 footnote, ensure the asterisked row ('Transient limb spasm') is clearly referenced; move the footnote text closer to the table if needed.

    Clarity in table footnotes avoids reader confusion.
12. 12.
    LOWcopyedit

    In Table 2, rename the sub-rows 'Production: Tell story' and 'Comprehension: Tell story' to 'Production (storytelling)' and 'Comprehension (story)' to avoid ambiguity.

    Clearer labelling improves readability.
13. 13.
    LOWcopyedit

    In Methods, 'Statistical analysis', rephrase 'The primary outcome was served as the change' to 'The primary outcome was defined as the change'.

    Corrects a grammatical error for clarity.
14. 14.
    LOWcopyedit

    In Table 3, for the Tinnitus row, change '0 (0)' to '0 (0.0)' for consistency with percentages shown to one decimal place.

    Formatting consistency improves professional appearance.